# mcrc-cetuximab-analysis

–ê–Ω–∞–ª–∏–∑ –º–æ–ª–µ–∫—É–ª—è—Ä–Ω—ã—Ö –º–µ—Ö–∞–Ω–∏–∑–º–æ–≤ —Ä–µ–∑–∏—Å—Ç–µ–Ω—Ç–Ω–æ—Å—Ç–∏ —Å–≤—è–∑–∞–Ω–Ω—ã—Ö —Å –≤—ã–∂–∏–≤–∞–µ–º–æ—Å—Ç—å—é –∏ –æ—Ç–≤–µ—Ç–æ–º –Ω–∞ —Ç–µ—Ä–∞–ø–∏—é —Ü–µ—Ç—É–∫—Å–∏–º–∞–±–æ–º —Å—Ä–µ–¥–∏ –ø–∞—Ü–∏–µ–Ω—Ç–æ–≤ —Å—Ç—Ä–∞–¥–∞—é—â–∏—Ö –æ—Ç –º–µ—Ç–∞—Å—Ç–∞—Ç–∏—á–µ—Å–∫–æ–≥–æ –∫–æ–ª–æ—Ä–µ–∫—Ç–∞–ª—å–Ω–æ–≥–æ —Ä–∞–∫–∞

–¶–µ–ª—å —Ä–∞–±–æ—Ç—ã
–ü–æ–Ω—è—Ç—å, –∫–∞–∫–∏–µ –º–æ–ª–µ–∫—É–ª—è—Ä–Ω—ã–µ –º–µ—Ö–∞–Ω–∏–∑–º—ã –º–æ–≥—É—Ç –±—ã—Ç—å —Å–≤—è–∑–∞–Ω—ã —Å –≤—ã–∂–∏–≤–∞–µ–º–æ—Å—Ç—å—é –∏ –æ—Ç–≤–µ—Ç–æ–º –Ω–∞ —Ç–µ—Ä–∞–ø–∏—é —Ü–µ—Ç—É–∫—Å–∏–º–∞–±–æ–º —É –ø–∞—Ü–∏–µ–Ω—Ç–æ–≤ —Å –º–µ—Ç–∞—Å—Ç–∞—Ç–∏—á–µ—Å–∫–∏–º –∫–æ–ª–æ—Ä–µ–∫—Ç–∞–ª—å–Ω—ã–º —Ä–∞–∫–æ–º (–º–ö–†–†). –û—Å–æ–±–æ–µ –≤–Ω–∏–º–∞–Ω–∏–µ –±—É–¥–µ—Ç —É–¥–µ–ª–µ–Ω–æ —Ä–æ–ª–∏ –≥–µ–Ω–∞ MET, –∞–∫—Ç–∏–≤–Ω–æ—Å—Ç–∏ —Å–∏–≥–Ω–∞–ª—å–Ω—ã—Ö –ø—É—Ç–µ–π MAPK –∏ PI3K, –∞ —Ç–∞–∫–∂–µ —ç–ø–∏—Ç–µ–ª–∏–∞–ª—å–Ω–æ-–º–µ–∑–µ–Ω—Ö–∏–º–∞–ª—å–Ω–æ–º—É –ø–µ—Ä–µ—Ö–æ–¥—É (EMT).


# SETUP INSTRUCTIONS

        curl https://pyenv.run | bash

Add to .bashrc: 

        export PATH="$HOME/.pyenv/bin:$PATH"
        eval "$(pyenv init --path)"
        eval "$(pyenv init -)"

Then:

        pyenv install 3.12.0
        pyenv global 3.12.0 

<<<<<<< HEAD
        cd YOUR_REPO_DIR
        python -m venv .venv
        source .venv/bin/activate
        pip install -r requirements.txt
=======
2. **Gene Expression & Biomarker Evaluation**
   - MET expression before/after treatment
   - EMT signature analysis (score and correlation with MET)

3. **Survival Analysis**
   - Kaplan-Meier survival curves by:
     - MET expression
     - EMT signature
     - CMS subtype
     - Transcriptomic clusters

4. **CMS Analysis**
   - CMS classification using CMScaller
   - Stacked bar plots by response, cohort, and clusters
   - Chi-square tests for CMS distribution differences

5. **Clustering & Immune Profiling**
   - ssGSEA enrichment for BG immune/stromal signatures
   - Visualization of clusters and heatmaps
   - Association with survival and CMS types

---

## üìä Key Results

- **MET expression** was **not significantly associated** with survival or treatment response.
- **EMT signature** showed stronger association patterns than single-gene markers, but still requires further validation.
- **CMS subtypes** revealed clear survival differences, with **CMS1 showing the poorest prognosis**.
- **Four tumor clusters** were identified, each with distinct CMS distributions, immune profiles, and survival trends.


---

## ‚ñ∂Ô∏è How to Run

1. Clone the repo:
   ```bash
   git clone https://github.com/lkmaks/mcrc-cetuximab-analysis
   cd mcrc-cetuximab-resistance
   ```

2. Set up environment (optional but recommended):
   ```bash
         pyenv install 3.12.0
         pyenv global 3.12.0 

         cd YOUR_REPO_DIR
         python -m venv .venv
         source .venv/bin/activate
         pip install -r requirements.txt
   ```

3. Run analysis:
   - Open notebooks in `notebooks/`
   - Follow step-by-step sections: 0->1->2->3->4->5->Elza

---

## üìå Limitations

- Sample size is limited in some subgroups (e.g., responders vs non-responders)
- Requires external validation in larger, independent cohorts
- EMT/MET not sufficient alone as predictive biomarkers

---

## üß† Conclusion

> **Single genes (e.g., MET) are insufficient predictors of resistance. Composite transcriptomic signatures and CMS/clustering provide more robust insight into cetuximab resistance mechanisms.**

---

## üîó Citation

If you use this repository, please cite:
```
A. X., M. Y., E. Z., D. Belousov. "Analysis of Molecular Mechanisms of Resistance Associated with Cetuximab Survival Response in mCRC Patients" (2025)
```

---

## üì¨ Contact

For questions or collaboration:
- [hommurat9001@gmail.com](mailto:hommurat9001@gmail.com)
>>>>>>> 09354341872f4d40c8f5adbb966c565424391fc1
